Cannabis Battle! 2 Pot Stocks With Very Different Futures

The pot industry is growing at a rapid pace, but choosing winning stocks is getting harder. Learn what makes Green Organic Dutchman (TSX:TGOD) a sell and Cronos Group Inc (TSX:CRON)(NYSE:CRON) a buy.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The cannabis market should continue to grow for the next decade and beyond. Many analysts believe the global market could surpass $100 billion in sales by 2030. In order to meet surging demand, pot companies have been ramping their capacity and infrastructure at breakneck speeds. They’ve also been working to secure valuable partnerships to accelerate market adoption.

Even if the pot industry continues to take off, however, it’s no guarantee that every cannabis company will succeed. Consider the solar industry. For 10 years straight, solar demand has continued to mount, yet the industry has seen dozens of bankruptcies.

The early internet was also a good example. In 1999, the internet had the vast majority of its growth days ahead of it, but that year saw hundreds of dot-com businesses disappear.

If you want to succeed investing in the marijuana industry, you’ll need to know which strategies will work and which ones won’t. There are no better examples of this than Green Organic Dutchman (TSX:TGOD) and Cronos Group Inc (TSX:CRON)(NYSE:CRON).

Avoid commoditization

If you invest in the pot market, know one thing: commoditization will ruin the party. At the end of the day, there’s not much differentiation between cannabis production. Compare it to something like wheat, corn, or soy, all of which are grown by commoditized farms fetching a market price.

Regulation is keeping supply limited, but we’ve already seen how cannabis pricing can collapse due to surging numbers of growers. In 2018, Oregon was reportedly “drowning in one million pounds of excess weed,” pushing down prices to historically low levels.

If you want to avoid commoditization, avoid companies like Green Organic, as Green Organic is positioned as a pure grower, with no differentiation apart from its organic focus.

While organic cannabis has fetched a higher price, it’s just as susceptible to steep pricing declines. Green Organic’s lack of differentiation was demonstrated when its former partner, Aurora Cannabis Inc, opted to terminate its agreement to buy 20% of its produce, choosing instead to source the cannabis elsewhere.

Wherever pot pricing goes, so too will Green Organic. That’s a risky bet as commoditization looms. Instead, choose companies that can better dictate their own future.

Brands and influence

Soda is a commodity, but you wouldn’t be able to tell looking at Coca-Cola Co. As a $250 billion behemoth, Coca-Cola has demonstrated that it can sustain high margins for decades at a time. Another example is cigarettes.

Tobacco is largely commoditized, yet firms like Altria Group Inc (formerly Philip Morris) continue to rake in billions every year. Learning from firms like Altria is critical for any pot company looking to capitalize long term. Fortunately, one cannabis firm has direct access.

Last year, Altria and Cronos agreed to a $1.8 billion partnership that should align each companies interest for the next decade and beyond. Altria is the most experienced partner conceivable when it comes to navigating a highly regulated, increasingly commoditized industry.

If any cannabis company succeeds, it should be Cronos. If Green Organic’s stock will follow cannabis pricing, Cronos’ stock should follow industry-wide growth. That’s a much better bet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »